ANI Pharmaceuticals Inc’s recently made public that its Officer NIKHIL S LALWANI acquired Company’s shares for reported $4.89 million on Aug 12 ’25. In the deal valued at $85.93 per share,56,960 shares were bought.
Then, THOMAS HAUGHEY bought 19,341 shares, generating $1,662,048 in total proceeds.
Before that, STEPHEN P CAREY bought 50,000 shares. ANI Pharmaceuticals Inc shares valued at $4,303,590 were divested by the Officer at a price of $86.07 per share.
H.C. Wainwright initiated its ANI Pharmaceuticals Inc [ANIP] rating to a Buy in a research note published on July 10, 2025; the price target was $84. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in mid March with a ‘”a Buy”‘ rating. JP Morgan began covering ANIP with “an Overweight” recommendation on March 12, 2025. Leerink Partners started covering the stock on December 11, 2024. It rated ANIP as “an Outperform”.
Price Performance Review of ANIP
On Tuesday, ANI Pharmaceuticals Inc [NASDAQ:ANIP] saw its stock jump 4.08% to $88.34. Over the last five days, the stock has gained 34.11%. ANI Pharmaceuticals Inc shares have risen nearly 56.55% since the year began. Nevertheless, the stocks have risen 59.80% over the past one year. While a 52-week high of $87.95 was reached on 08/12/25, a 52-week low of $52.50 was recorded on 01/13/25.
Levels Of Support And Resistance For ANIP Stock
The 24-hour chart illustrates a support level at 85.47, which if violated will result in even more drops to 82.59. On the upside, there is a resistance level at 89.79. A further resistance level may holdings at 91.23.
How much short interest is there in ANI Pharmaceuticals Inc?
A steep rise in short interest was recorded in ANI Pharmaceuticals Inc stocks on 2025-07-31, growing by 0.2 million shares to a total of 2.21 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-30 was 2.0 million shares. There was a rise of 9.26%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 11, 2024 when Piper Sandler began covering the stock and recommended ‘”an Overweight”‘ rating along with a $68 price target.
